Any current/future new fundraising through debt or equity?

There is no mention of any current or future fundraising through debt or equity in the provided transcript. The company is focused on executing its existing capex plans totaling INR 1,100 crores, primarily funded through internal resources. INR 800 crores of the capex is allocated for the Dahej site, INR 50 crores for the Fluoro-intermediate project (pending completion), INR 90 crores for world-scale ethyl acetate, and a portion for refurbishment and upgrades. Leadership emphasized disciplined project tracking under a Chief Technology Officer without indicating plans for raising external capit

Any current/future capex/capital investment/strategic investment?

Total planned capex of INR 1,100 crores beyond the earlier Fluoro intermediate project. INR 800 crores allocated for the Dahej site, including n-Butyl acetate. INR 90 crores for a world-scale Ethyl Acetate plant at Lote. INR 50 crores incremental capex pending for the Fluoro-intermediate project. Additional smaller refurbishment capex for n-propyl acetate at existing sites. Midpoint of expenditure for Dahej-related capex expected in the first half of FY '26. Total Fluoro-intermediate project cost to complete is INR 550 crores (INR 500 crores already spent). Expected to double sales from INR 2,

Future growth expectations in sales/revenue/volumes?

Laxmi Organic targets doubling sales from INR 2,800 crores in FY '24 to FY '28, driven by INR 1,100 crores planned capex (Page 8). Fluoro-intermediates business is expected to reach 40%-60% of a peak revenue of INR 200 crores by FY '26 (Pages 6, 8). Specialty business pipeline remains strong with 11+ products, 60% fluoro-heavy, 40% other derivatives; focus on commercialization and capex for growth (Page 9). Export growth is positive, with 36% of overall sales, helping derisk currency impact (Page 5). Operational excellence efforts expected to sustain volume growth in both Essentials and Specia

Future growth expectations in earnings/operating earnings/profits/EPS?

Laxmi Organic targets strong profitable volume and EBITDA growth through FY '25 and beyond, driven by operational excellence and new product launches. The Fluoro-Intermediate project at Lote is expected to achieve 40%-60% of peak revenues (INR 200 crores peak revenue) by FY '26, with targeted EBITDA margins of 20%-25%. The INR 1,100 crores capex plan aims to double sales from INR 2,800 crores in FY '24 to FY '28, with Essentials business EBITDA margins of 8%-12% and Specialty margins of 20%-25%. The company expects margins to improve due to better product mix, operational efficiencies, and sta

Current/ Expected Orderbook/ Pending Orders?

The pipeline for new business remains strong and is getting revitalized. Approximately 60% of the new business pipeline is focused on fluoro-related products. The remaining 40% of the pipeline consists of other chemical derivatives. The company is diligently working on commercializing these products and securing capex to monetize the pipeline. The fluoro-intermediates project at the Lote site is targeting about 10% of peak revenues in Q4 and aims for 40%-60% of peak revenues by FY '26. All key products contributing to FY '26 revenues have been successfully commercialized at the Lote facility.

IN US

Sale is live|00:00:00left today

Laxmi Organic Industries LtdQ4 FY26Chemicals & Petrochemicals

Laxmi Organic Industries Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹163P/E: 53.1Market Cap: ₹4.2K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Laxmi Organic targets doubling sales from INR 2,800 crores in FY '24 to FY '28, driven by INR 1,100 crores planned capex (Page 8).
→Fluoro-intermediates business is expected to reach 40%-60% of a peak revenue of INR 200 crores by FY '26 (Pages 6, 8).
→Specialty business pipeline remains strong with 11+ products, 60% fluoro-heavy, 40% other derivatives; focus on commercialization and capex for growth (Page 9).
→Export growth is positive, with 36% of overall sales, helping derisk currency impact (Page 5).
→Operational excellence efforts expected to sustain volume growth in both Essentials and Specialty segments (Pages 5, 10, 12).
→Growth in CASE industry, pigments, and pharma segments supported by global MNC clients (Page 6).
→Agro segment currently weak but anticipated to recover over time (Page 9).

Margin guidance

Category 3

→Laxmi Organic targets strong profitable volume and EBITDA growth through FY '25 and beyond, driven by operational excellence and new product launches.
→The Fluoro-Intermediate project at Lote is expected to achieve 40%-60% of peak revenues (INR 200 crores peak revenue) by FY '26, with targeted EBITDA margins of 20%-25%.
→The INR 1,100 crores capex plan aims to double sales from INR 2,800 crores in FY '24 to FY '28, with Essentials business EBITDA margins of 8%-12% and Specialty margins of 20%-25%.
→The company expects margins to improve due to better product mix, operational efficiencies, and stable raw material prices.
→Sustainability ratings and safety recognitions reflect strong governance and can support long-term performance.
→Overall growth is expected with doubled sales by FY '28 and improving EBITDA margins, positioning the company for strong earnings and EPS expansion.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or future fundraising through debt or equity in the provided transcript.
→The company is focused on executing its existing capex plans totaling INR 1,100 crores, primarily funded through internal resources.
→INR 800 crores of the capex is allocated for the Dahej site, INR 50 crores for the Fluoro-intermediate project (pending completion), INR 90 crores for world-scale ethyl acetate, and a portion for refurbishment and upgrades.
→Leadership emphasized disciplined project tracking under a Chief Technology Officer without indicating plans for raising external capital.
→No explicit discussions or announcements regarding new debt or equity fundraising were made during the call.

Order book

Yes

→The pipeline for new business remains strong and is getting revitalized.
→Approximately 60% of the new business pipeline is focused on fluoro-related products.
→The remaining 40% of the pipeline consists of other chemical derivatives.
→The company is diligently working on commercializing these products and securing capex to monetize the pipeline.
→The fluoro-intermediates project at the Lote site is targeting about 10% of peak revenues in Q4 and aims for 40%-60% of peak revenues by FY '26.
→All key products contributing to FY '26 revenues have been successfully commercialized at the Lote facility.

Capex plans

Yes

→Total planned capex of INR 1,100 crores beyond the earlier Fluoro intermediate project.
→INR 800 crores allocated for the Dahej site, including n-Butyl acetate.
→INR 90 crores for a world-scale Ethyl Acetate plant at Lote.
→INR 50 crores incremental capex pending for the Fluoro-intermediate project.
→Additional smaller refurbishment capex for n-propyl acetate at existing sites.
→Midpoint of expenditure for Dahej-related capex expected in the first half of FY '26.
→Total Fluoro-intermediate project cost to complete is INR 550 crores (INR 500 crores already spent).
→Expected to double sales from INR 2,800 crores in FY '24 to FY '28 driven by ongoing capex.
→Emphasis on operational excellence, capacity augmentation, and customer centricity to drive growth.
→Robust project tracking under CTO leadership for transparency and timely execution.

How does Laxmi Organic Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Laxmi Organic Industries Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Laxmi Organic Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio